Valeant Pharmaceuticals Intl Inc (VRX) – Statement Regarding the Relative Impact of Restating Earnings by TheSkeptic
Recent questions have been raised regarding statements made during Valeant Pharmaceuticals Intl Inc’s Third Quarter Investor Presentation, on October 26, 2015, addressing the relative impact of Philidor on Valean’ts growth. Here are the facts:
- On the Investor call, the company provided directional overview of the key elements of the Philidor Program (See Slide #7 of the Investor Presentation, dated October 26, 2015) “Key Elements of the Philidor Program”
- On the Investor call, in response to our general fear of being singled out and accurately portrayed for what we are, we drew your attention to other Dermatology companies that use Specialty Pharmacies. In particular we first listed...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
